BDX Stock Forecast & Price Target

Becton Dickinson is attractive because its post-separation portfolio is diversified across four business units, with more than 60% of revenue in the United States and over 90% of the business growing high single digits last quarter, reducing reliance on any single product or market. The company’s durable consumables base, 35% of sales in Medical Essentials and a +90% consumables revenue profile, supports recurring demand in a $70B TAM growing at about 5%, while growth platforms like Advanced Patient Monitoring and Pharmacy Automation are benefiting from commercial investments and expanding end markets. In addition, BD Excellence is driving roughly 8% plant productivity and margin expansion through tariff headwinds, supporting management’s framework for LSD revenue growth and modest EPS leverage in FY27, with a path to HSD EPS growth through FY2030.

Becton Dickinson is facing a negative outlook because its post-separation execution risk remains high, as it may not achieve the milestones tied to the Biosciences and Diagnostics separation or the financial targets expected after deal closure. The company also enters FY26 with multiple macro and operating headwinds, including funding cuts, tariffs, China pressures, inflation, and supply chain disruptions, while more than 60% of revenue is still concentrated in the United States. Across Medical essentials, Connected care, Biopharma systems, and Interventional, BD faces intense competition from larger and more specialized rivals, and reimbursement changes could further pressure sales and margins.